XML 15 R5.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Statements of Stockholders' Equity - USD ($)
Common stock
Series A Common Stock
Common stock
Series B Common Stock
Additional paid-in capital
Accumulated deficit
Accumulated Other Comprehensive (Loss) Income
Series A Common Stock
Series B Common Stock
Total
Beginning balance at Dec. 31, 2023 $ 2,000   $ 340,777,000 $ (249,744,000) $ 30,000     $ 91,065,000
Beginning balance (in shares) at Dec. 31, 2023 21,375,402 1,520,490            
Increase (Decrease) In Stockholders' Deficit                
Sale of Series A common stock, net of issuance costs $ 1,000   104,731,000         104,732,000
Sale of Series A common stock, net of issuance costs (in shares) 9,000,000              
Issuance of Series A Common Stock upon exercise of stock options     114,000         114,000
Issuance of Series A Common Stock upon exercise of stock options (in shares) 17,995              
Stock-based compensation expense     759,000         759,000
Unrealized loss on marketable securities         (23,000)     (23,000)
Net loss       (6,629,000)       (6,629,000)
Ending balance at Mar. 31, 2024 $ 3,000   446,381,000 (256,373,000) 7,000     190,018,000
Ending balance (in shares) at Mar. 31, 2024 30,393,397 1,520,490            
Beginning balance at Dec. 31, 2023 $ 2,000   340,777,000 (249,744,000) 30,000     91,065,000
Beginning balance (in shares) at Dec. 31, 2023 21,375,402 1,520,490            
Increase (Decrease) In Stockholders' Deficit                
Unrealized loss on marketable securities               411,000
Net loss               (29,366,000)
Ending balance at Sep. 30, 2024 $ 3,000   449,349,000 (279,110,000) 441,000     170,683,000
Ending balance (in shares) at Sep. 30, 2024 30,674,855 1,520,490            
Beginning balance at Mar. 31, 2024 $ 3,000   446,381,000 (256,373,000) 7,000     190,018,000
Beginning balance (in shares) at Mar. 31, 2024 30,393,397 1,520,490            
Increase (Decrease) In Stockholders' Deficit                
Issuance costs related to sale of Series A common stock     (27,000)         (27,000)
Stock-based compensation expense     1,449,000         1,449,000
Unrealized loss on marketable securities         (30,000)     (30,000)
Net loss       (8,118,000)       (8,118,000)
Ending balance at Jun. 30, 2024 $ 3,000   447,803,000 (264,491,000) (23,000)     183,292,000
Ending balance (in shares) at Jun. 30, 2024 30,393,397 1,520,490            
Increase (Decrease) In Stockholders' Deficit                
Issuance of Series A Common Stock for vesting of restricted stock units (in shares) 281,458              
Stock-based compensation expense     1,546,000         1,546,000
Unrealized loss on marketable securities         464,000     464,000
Net loss       (14,619,000)       (14,619,000)
Ending balance at Sep. 30, 2024 $ 3,000   449,349,000 (279,110,000) 441,000     170,683,000
Ending balance (in shares) at Sep. 30, 2024 30,674,855 1,520,490            
Beginning balance at Dec. 31, 2024 $ 3,000   450,883,000 (295,311,000) 230,000     155,805,000
Beginning balance (in shares) at Dec. 31, 2024 30,674,855 1,520,490       30,674,855 1,520,490  
Increase (Decrease) In Stockholders' Deficit                
Stock-based compensation expense     1,472,000         1,472,000
Unrealized loss on marketable securities         (109,000)     (109,000)
Net loss $ 0 $ 0 0 (18,176,000) 0     (18,176,000)
Ending balance at Mar. 31, 2025 $ 3,000   452,355,000 (313,487,000) 121,000     138,992,000
Ending balance (in shares) at Mar. 31, 2025 30,674,855 1,520,490            
Beginning balance at Dec. 31, 2024 $ 3,000   450,883,000 (295,311,000) 230,000     $ 155,805,000
Beginning balance (in shares) at Dec. 31, 2024 30,674,855 1,520,490       30,674,855 1,520,490  
Increase (Decrease) In Stockholders' Deficit                
Issuance of Series A Common Stock upon exercise of stock options (in shares)               44,792
Unrealized loss on marketable securities               $ (113,000)
Net loss               (41,470,000)
Ending balance at Sep. 30, 2025 $ 3,000   455,916,000 (336,781,000) 117,000     119,255,000
Ending balance (in shares) at Sep. 30, 2025 31,001,109 1,520,490       31,001,109 1,520,490  
Beginning balance at Mar. 31, 2025 $ 3,000   452,355,000 (313,487,000) 121,000     138,992,000
Beginning balance (in shares) at Mar. 31, 2025 30,674,855 1,520,490            
Increase (Decrease) In Stockholders' Deficit                
Issuance of Series A Common Stock for vesting of restricted stock units     1,000         1,000
Issuance of Series A Common Stock for vesting of restricted stock units (in shares) 99              
Stock-based compensation expense     1,598,000         1,598,000
Unrealized loss on marketable securities         (45,000)     (45,000)
Net loss       (10,386,000)       (10,386,000)
Ending balance at Jun. 30, 2025 $ 3,000 $ 1,520,490 453,954,000 (323,873,000) 76,000     130,160,000
Ending balance (in shares) at Jun. 30, 2025 30,674,954              
Increase (Decrease) In Stockholders' Deficit                
Issuance of Series A Common Stock upon exercise of stock options     274,000         274,000
Issuance of Series A Common Stock upon exercise of stock options (in shares) 44,693              
Issuance of Series A Common Stock for vesting of restricted stock units (in shares) 281,462              
Stock-based compensation expense     1,688,000         1,688,000
Unrealized loss on marketable securities         41,000     41,000
Net loss       (12,908,000)       (12,908,000)
Ending balance at Sep. 30, 2025 $ 3,000   $ 455,916,000 $ (336,781,000) $ 117,000     $ 119,255,000
Ending balance (in shares) at Sep. 30, 2025 31,001,109 1,520,490       31,001,109 1,520,490